Guarded temporary access

The administration finalizes a temporary pathway for selected restricted peptides, but FDA keeps prescription, sterility, labeling, and adverse-event reporting requirements. This is the most likely outcome because it fits RFK Jr.'s access agenda while giving FDA a defensible safety framework.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.